Colorectal Cancer

alkiviadis.1961 shared this article with you from Inoreader Association of Adherence to Quality Metrics with Recurrence or Mortality among Veterans with Colorectal Cancer Via Latest Results for Journal of Gastrointestinal Surgery Abstract Background The National Comprehensive Cancer Network has defined metrics for colorectal cancer; however, the association of metric adherence with patient clinical outcomes remains underexplored. The study aim was to evaluate the association of National Comprehensive Cancer Network metric adherence with recurrence and mortality in Veterans with nonmetastatic colorectal cancer. Methods Veterans with stage I–III colorectal cancer who underwent non-emergent resection from 2001 to 2015 at a single Veterans Affairs Medical Center were included. The primary predictor was completion of eligible National Comprehensive Cancer Network metrics. The primary outcome was a composite of recurrence or all-cause death in three phases of care: surgical (up to 6 months after resection), treatment (6–18 months after resection), and surveillance (18 months–3 years after resection). Hazard ratios were estimated via Cox proportional hazards regression in a propensity score–weighted cohort. Results A total of 1107 electronic medical records of patients undergoing colorectal surgery were reviewed, and 379 patients were included (301 colon and 78 rectal cancer). In the surgical phase, the weighted analysis yielded a hazard ratio of 0.37 (95% confidence interval 0.12–1.13) for metric-adherent patients compared with non-adherent patients. In the treatment and surveillance phases, the hazard ratios for metric-adherent care were 0.68 (95% confidence interval 0.25–1.85) and 0.91 (95% confidence interval 0.31–2.68), respectively. Conclusions The National Comprehensive Cancer Network guideline metric adherence was associated with a lower rate of recurrence and death in the surgical phase of care among stage I–III patients with resected colorectal cancer. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.